crimean-congo hemorrhagic fever is a fatal viral disease that occurs in some parts of africa, asia, eastern europe and the middle-east. primarily it is a zoonosis but can be seen sporadically in humans. recently outbreaks have been reported from pakistan, afghanistan, saudi arabia, united arab emirates and iran. in this retrospective study, we evaluated the efficacy of oral ribavirin in the tre...

BACKGROUND/AIM In this observational study, the effects of oral ribavirin on clinical and laboratory parameters and blood products use in patients with Crimean-Congo hemorrhagic fever (CCHF) were evaluated. MATERIALS AND METHODS CCHF patients (n = 100) who were hospitalized between 2007 and 2010 were included. Oral ribavirin was administered to 56 patients with symptom duration less than 5 da...

abstract crimean-congo hemorrhagic fever (cchf) is a tick-borne viral disease reported from more than 30 countries in africa, asia, south-east europe, and the middle east. laboratory findings include prolonged prothrombin, bleeding, and activated partial thromboplastin times. diagnostic methods include antibody detection by enzyme-linked immunosorbent assay (elisa), virus isolation, antigen det...

We compared the mortality rate among patients suspected of having Crimean-Congo hemorrhagic fever (CCHF) who received treatment with oral ribavirin and those who did not. Ninety-seven (69.8%) of 139 treated patients suspected of having CCHF survived, and 61 (88.9%) of 69 treated patients with confirmed CCHF survived. The efficacy of oral ribavirin was 80% among patients with confirmed CCHF and ...

BACKGROUND Paramyxovirus (PV) infections are increasingly recognized in lung transplant recipients and have been linked to subsequent graft failure and bronchiolitis obliterans syndrome (BOS). Ribavirin represents a possible treatment option although the outcome on graft function and BOS incidence is unknown. METHODS We analysed outcomes of all PV infections in lung/heart-lung recipients betw...

Eleven pediatric patients, aged 1 to 10 years and with symptomatic human immunodeficiency virus infection, were treated with 6 or 10 mg of oral ribavirin per kg of body weight daily for 60 days. Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic evaluations. The children tolerated the drug well, and treatment was not associated with any clinica...

Although ribavirin is minimally cleared by renal elimination, its pharmacokinetics are substantially altered in patients with chronic renal impairment. This open-label study assessed the pharmacokinetics of single 400-mg oral and intravenous (IV) doses of ribavirin in two healthy volunteers and 12 patients with varying degrees of chronic renal impairment. Blood and urine samples were collected ...

Crimean-Congo Hemorrhagic Fever is a fatal viral disease that occurs in some parts of Africa, Asia, Eastern Europe and the Middle-East. Primarily it is a zoonosis but can be seen sporadically in humans. Recently outbreaks have been reported from Pakistan, Afghanistan, Saudi Arabia, United Arab Emirates and Iran. In this retrospective study, we evaluated the efficacy of oral Ribavirin in the...

Over the past two decades, ribavirin has been an integral component of treatment for hepatitis C virus (HCV) infection, where it has been shown to improve the efficacy of (pegylated) interferon. However, because of treatment-limiting side effects and its additive toxicity with interferon, the search for interferon- and ribavirin-free regimens has been underway. The recent approvals of all-oral ...

A loading dose and short-term administration of oral ribavirin significantly improved symptoms and signs of influenza type A or B infection in 25 patients. The antiviral effect was not significant. No adverse clinical effects or significant laboratory values were observed. Oral treatment of patients with influenza A or B infection might be possible with ribavirin.